Communiqués FamiCord AG OTC Markets

Actions

VTIAF

DE000A0BL849

Installations et services en soins de santé

Marché Fermé - OTC Markets 20:53:14 07/07/2026			Varia. 5j.	Varia. 1 janv.
3,390 ^USD	-46,82%		-.--%	-46,82%

28/08	FamiCord AG publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/08	FamiCord AG confirme ses prévisions de résultats pour l'exercice 2026	CI

Communiqués

28/08	FamiCord significantly improves operating cash flow in Q2 2026 amid persistently challenging business environment	EQ
18/08	FamiCord AG to transfer to the Scale segment effective 19 August 2026	EQ
29/06	Management Board of FamiCord AG resolves on intended transfer of stock exchange listing from the regulated market (Prime Standard) to the Scale segment of the Frankfurt Stock Exchange	EQ
23/06	FamiCord AG wins ArThec as another customer in its CDMO business area	EQ
29/05	FamiCord AG records weaker start to 2026 financial year as expected amid continued market headwinds while subscription base remains robust	EQ
11/05	FamiCord : Remuneration Report 2025 (01 FamiCord AG Remuneration Report 2025 2)	PU
30/04	FamiCord AG closes financial year 2025 with overall solid year-end business while preparing for increasing macroeconomic and political headwinds	EQ
30/04	FamiCord : Declaration of Conformity 2026	PU
30/04	FamiCord : Declaration on Corporate Governance 2025	PU
15/04	FamiCord AG publishes preliminary figures for 2025 and outlook for 2026	EQ
27/11	FamiCord : Unternehmenspräsentation (20251125 FamiCord EKF2025)	PU
21/11	FamiCord AG accelerates profitable growth in the third quarter of 2025 and further strengthens quality and visibility of revenues	EQ
16/09/25	FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland	EQ
10/09/25	FamiCord : The first method for expanding umbilical cord blood stem cells has received authorization from the European Commission	PU
28/08/25	FamiCord : Company presentation (20250827 FAM H12025 Presentation ENG 1)	PU
28/08/25	FamiCord : Company presentation (20250827 FAM H12025 Presentation ENG)	PU
27/08/25	FamiCord : Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells	PU
27/08/25	FamiCord : Company presentation (20250827 FAM H12025 Presentation ENG fin short )	PU
27/08/25	FamiCord : Company presentation (20250827 FAM H12025 Presentation ENG fin)	PU
27/08/25	FamiCord AG significantly increases revenue and earnings in the first half of 2025 and shifts focus even more strongly to core business in the future	EQ
27/06/25	FamiCord : Compensation system Supervisory Board (FamiCord AG Remunerationsystem SB)	PU
03/06/25	FamiCord : Dubai Laboratory Earns Prestigious AABB Accreditation	PU
28/05/25	FamiCord AG acquires majority stake in Národní Centrum Pupečníkové Krve and Rodinná banka perinatálnych a mezenchymálnych buniek	EQ
28/05/25	FamiCord AG starts 2025 financial year with accelerated growth and increases profitability at almost all earnings levels	EQ
15/05/25	FamiCord : Remuneration Report 2024 (FamiCord AG Verguetungsbericht 2024 Eng)	PU